Please login to the form below
Incyte
Incyte/Merck trial failure bodes ill for IDO class
Incyte/Merck trial failure bodes ill for IDO class. The much-touted cancer immunotherapy combination fails to show improvement over Keytruda alone. ... Ahead of the weekend, Incyte and partner Merck &Co were rocked by the news that their much-touted
Sanofi’s PD-1 inhibitor starts EU review for skin cancer
In addition to chasing companies in the category with already-marketed drugs - which also include Roche, AstraZeneca and Merck KGaA/Pfizer - Novartis’PDR001 and INCSHR-1210 from Incyte/Jiangsu Hengrui are
Deal Watch January 2018
Option, collaboration. 1, 063. Syros Pharmaceuticals/ Incyte. Gene control platform to identify up to seven therapeutic targets with a focus in myeloproliferative neoplasms.
Celgene boosts haematology pipeline with $7bn Impact Bio deal
to Incyte and Novartis’rival JAK inhibitor Jakafi (ruxolitinib), which grew 35% to $831m in the first nine months of 2017.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
Featured jobs
-
Senior Programme Executive
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Account Manager – Med Comms – London
-
Salary TBC
- Editor – Medical Education Agency – Bucks
-
Salary TBC
Subscribe to our email news alerts
- BenevolentAI raises $115m to fund drug development
- Shire rebuffs Takeda bids, as Allergan bows out
- Abeona Therapeutics names CEO
- Zelluna Immunotherapy appoints chief technology officer
- Spirit Health Group offers new market access consultancy service
- Why heading online for scientific meetings can yield greater HCP engagement
PMHub
Streaming Well
Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....
Latest intelligence
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Quick links
Infographics
